rozanolixizumab: Clinical Trials

12 trials of rozanolixizumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 terminated, 2 active not recruiting, 2 recruiting. 12 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 5, Terminated 3, Active not recruiting 2, Recruiting 2
Phase 21Completed 1

Follow rozanolixizumab: new trials by email Literature Review of rozanolixizumab trials Research Report on rozanolixizumab

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Rozanolixizumab - Ocular Myasthenia Gravis
Phase 3RecruitingUCB Biopharma SRL1002026-09-162026-11-06
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Rozanolixizumab, Placebo - Ocular Myasthenia Gravis
Phase 3RecruitingUCB Biopharma SRL1202026-05-272026-11-06
An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis
rozanolixizumab - Generalized Myasthenia Gravis
Phase 3Active not recruitingUCB Biopharma SRL132024-10-082026-11-06
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
rozanolixizumab - Generalized Myasthenia Gravis
Phase 2 / Phase 3CompletedUCB Biopharma SRL142024-06-142026-10-27
A Phase 3, Open-label, Crossover Study to Evaluate Self-administration of Rozanolixizumab by Study Participants With Generalized Myasthenia Gravis (gMG)
Rozanolixizumab - Generalized Myasthenia Gravis
Phase 3CompletedUCB Biopharma SRL622023-04-172025-11-06
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
Rozanolixizumab, Placebo - Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)
Phase 3Active not recruitingUCB Biopharma SRL1132022-02-022026-10-27
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Rozanolixizumab - Generalized Myasthenia Gravis
Phase 3CompletedUCB Biopharma SRL1652021-02-032026-08-20
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Rozanolixizumab - Primary Immune Thrombocytopenia
Phase 3TerminatedUCB Biopharma SRL432021-01-062024-02-05
A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Rozanolixizumab, Placebo - Primary Immune Thrombocytopenia
Phase 3TerminatedUCB Biopharma SRL302020-06-032023-08-08
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
Rozanolixizumab, Placebo - Primary Immune Thrombocytopenia
Phase 3TerminatedUCB Biopharma SRL332020-01-312025-03-18
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Rozanolixizumab - Generalized Myasthenia Gravis
Phase 3CompletedUCB Biopharma SRL712019-10-292026-08-20
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
Rozanolixizumab, Placebo - Generalized Myasthenia Gravis
Phase 3CompletedUCB Biopharma SRL2002019-06-032026-08-20

Conditions studied

Myasthenia Gravis (8)  ·  Purpura, Thrombocytopenic, Idiopathic (3)  ·  Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (1)

Sponsors

UCB Biopharma SRL (12)

Countries

Poland (12)  ·  Japan (11)  ·  United States (10)  ·  Italy (9)  ·  Spain (9)  ·  France (8)  ·  Germany (8)  ·  Georgia (7)  ·  Russia (6)  ·  Taiwan (6)  ·  United Kingdom (6)  ·  Canada (5)  ·  China (4)  ·  Czechia (4)  ·  Ukraine (4)

Results publications

PMID 37059507, PMID 42388397, PMID 40105996, PMID 33219142, PMID 35674086, PMID 38099334, PMID 38978809, PMID 39297052, PMID 39552477, PMID 40755069, PMID 41074934, PMID 41205003

NIH funding

2019 (5), 2025 (2), 2023 (1)